Seres Therapeutics (MCRB) Misses Q1 EPS by 8c, Revenues Miss

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.39), $0.08 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $5.72 million versus the consensus estimate of $6.45 million.

“We continue to make steady progress across our broad microbiome pipeline and we look forward to an eventful remainder of the year with important clinical milestones,” said Eric Shaff, President and Chief Executive Officer of Seres. “Our SER-287 ECO-RESET Phase 2b study in mild-to-moderate ulcerative colitis patients is fully enrolled and we anticipate topline clinical results in mid-year. Following successful SER-109 Phase 3 pivotal results in patients with recurrent C. difficile infection, we continue to enroll an open label study to expand our safety database. We are very pleased with the pace of study enrollment and we anticipate achieving target enrollment during the third quarter of 2021. Completion of the required SER-109 safety database will support a Biologics License Application (BLA) filing, and potentially pave the way for SER-109 to become the first-ever FDA-approved microbiome therapeutic.”

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• ConAgra Brands board member Chirico to step down at annual meeting
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity